Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JANX014 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | JANX014 will be administered at increasing dose levels per cohort to determine the maximum tolerated dose. |
| Dose Expansion | EXPERIMENTAL | Participants will be dosed at levels previously declared tolerable. |
| Name | Type | Description |
|---|---|---|
| JANX014 | BIOLOGICAL | JANX014 will be administered via IV dosing |
Inclusion Criteria: * Male ≥18 years of age at the time of signing informed consent * Histologically or cytologically confirmed adenocarcinoma of the prostate * For Dose Escalation: Having mCRPC that progressed after at least one novel anti-androgen therapy and at least one taxane containing regime...
Top 20 of 53 competitors
JANX014 is an investigational monoclonal antibody being developed for the treatment of prostate cancer, specifically metastatic castration-resistant prostate cancer. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
JANX014 targets PSMA, a protein commonly expressed on prostate cancer cells. By binding to PSMA, the antibody is designed to deliver a therapeutic effect directly to the tumor. This mechanism is being evaluated in an ongoing Phase 1 clinical trial.
JANX014 is being developed by Janux Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol JANX. The company is conducting a Phase 1 clinical trial to evaluate the safety and efficacy of JANX014 in patients with metastatic castration-resistant prostate cancer.
JANX014 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or any other regulatory agency. The ongoing Phase 1 trial is actively recruiting participants to assess the drug's safety, tolerability, and preliminary efficacy.
JANX014 is being studied in a single Phase 1 clinical trial with the identifier NCT07545811. This trial is titled 'Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer' and is currently recruiting participants in the United States. The trial is expected to enroll approximately 43 male patients aged 18 years and older.
No alternative names for JANX014 have been reported. It is a distinct investigational monoclonal antibody being developed by Janux Therapeutics. Patients and healthcare providers should refer to the drug by its assigned name, JANX014, when discussing the ongoing clinical trial or potential treatment options.